-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 30, 2021, Sanofi and Regeneron announced that the dupilumab injection (dupilumab, English trade name), jointly developed by the two companies, will be treated for 6 months.
Duplizumab is a fully human monoclonal antibody that can inhibit the signal transduction of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways
The primary endpoint in this phase 3 trial is the proportion of patients achieving complete or almost clear skin symptoms (IGA score of 0 or 1), and the proportion of patients achieving a 75% improvement in the area and severity index of eczema (EASI-75)
In the trial, the drug showed safety results similar to its known safety profile for the treatment of atopic dermatitis
AD is a chronic type 2 inflammatory disease, 85%-90% of patients are younger than 5 years old
Reference materials:
[1] Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months.
